Core Insights - Verily, Alphabet's life sciences company, has announced staff cuts and the discontinuation of its devices program as part of a strategic refocus towards AI and infrastructure development [1][2][5] - The decision to wind down the devices program is attributed to the inability to support the necessary investment for long-term growth and scaling [3][10] Company Strategy - Verily has been on a journey to streamline operations and cut costs since 2023, focusing on precision health, data, and AI strategies [2][5] - The company aims to become a fully independent entity, gradually detaching from the technology and services shared with Google [6] Workforce Impact - The exact number of employees affected by the cuts has not been disclosed, but the company has made workforce reductions across various departments [4][7] - Employee benefits have been reduced, and salary bands have been adjusted to align with the healthcare industry rather than the technology sector [7] Devices Program Legacy - The devices program was responsible for several innovative projects, including a clinical study watch and a partnership with Dexcom for a wearable glucose sensor [3][9] - The company acknowledges the significant contributions of employees in the devices organization, highlighting their dedication and impact on healthcare technology [4][11]